Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Updated Nov 7, 2026
Ionis Pharmaceuticals, Inc. (IONS) shares rose 1.6% to $39.42 as of November 7, 2026, a modest gain from the prior close of $38.80. BestStocks flagged the session as a major change for IONS. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
IONS climbed 1.6% to $39.42
IONS rose 1.6% in its latest session, moving from $38.80 to $39.42.
RiskLow confidence
Rel. volume
0.8×
Below Avg
Vs peers
—
No comparable peers
Market cap
$6.6B
NASDAQ Global Select
Analyst target
$85
+115.4% vs price
Price chart
Oct 7 – Nov 6
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 1.6% session move. Weighing against that: Ionis Pharmaceuticals fell 2.30% to $39.23 intraday, with trading volume at 0.51x the time-adjusted average, suggesting below-normal participation; Ionis Pharmaceuticals fell 2.20% to $42.71, continuing a persistent technical downtrend that has erased roughly 45% of year-to-date value with no major company-specific negative catalyst released this morning. Wall Street's consensus price target sits at $84.92, implying +115.4% upside from $39.42. Over the past 90 days analysts logged 2 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (40/100). With earnings roughly 2 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $39.42, up $0.62 (+1.60%) from the previous close of $38.80. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $38.80 and $45.40, and it currently sits about 9% of the way up that band.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $84.92, 115.4% above the recent $39.42. Over the past 90 days analysts logged 2 upgrades, 13 maintains, and 1 downgrade. Here is how the bullish and bearish cases on IONS line up.
▲ The bullish case
+Wall Street's consensus price target of $84.92 implies +115.4% upside from $39.42.
+The Street's most bullish target is $115.00 (+191.7%).
+2 analyst upgrades in the past 90 days, most recently BMO Capital to Outperform (2026-10-22).
+Material positive event.
+Positive 1.6% session move.
▼ The bearish case
−1 analyst downgrade in the past 90 days, most recently BMO Capital to Market Perform (2026-08-19).
−Ionis Pharmaceuticals fell 2.30% to $39.23 intraday, with trading volume at 0.51x the time-adjusted average, suggesting below-normal participation.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 7, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Analyst expectations
Consensus target: $85+115.4%
↑ 2 upgrades= 13 maintains↓ 1 downgrades
BMO Capital upgraded to Outperform · 2026-10-22
SEC filings watch
No recent filings
Peer context
IONS+1.6%
Previous notable changes for IONS
News2026-11-02-5.2%
Ionis scheduled Q3 2026 earnings webcast for November 9 to discuss financial results and program progress.
Material / Earnings2026-11-02-5.2%
Ionis Pharmaceuticals, Inc. (IONS) moved −5.54% from $43.66 to $41.24 on 2026-11-02. We checked news, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The stock reached a new 30-day low; volume was near its 5-day average.
News2026-10-23-2.2%
Roche's Phase 3 data shows sefaxersen significantly reduced proteinuria in IgA nephropathy patients, validating Ionis' antisense therapy approach.
News2026-10-16-2.7%
CHMP recommends EU approval for TRYNGOLZA (olezarsen) in severe hypertriglyceridemia, expanding the drug's indication.
Ionis Pharmaceuticals fell 2.20% to $42.71, continuing a persistent technical downtrend that has erased roughly 45% of year-to-date value with no major company-specific negative catalyst released this morning. The stock remains under pressure near its 52-week low of $42.63, weighed by lingering effects from earlier 2026 trial setbacks including the failed Phase 3 CARDIO-TTRansform trial of eplontersen in July and Novartis' failed Phase 3 Lp(a)HORIZON trial for pelacarsen in September. Volume is tracking at 0.28x expected levels 120 minutes into the session.
Ionis Pharmaceuticals, Inc. moved -5.49% intraday from $45.75 to $43.24. ### 📉 Ionis Pharmaceuticals (NASDAQ: IONS ) Slump Ionis Pharmaceuticals shares remain under pressure due to lingering fallout from partner Novartis’ late-stage clinical trial setbacks. ### ⚠️ Key Pressures Weighing on the Stock - Trial Failures: Partner Novartis announced a Phase 3 miss for pelacarsen, followed by a late-stage setback for del-desiran in myotonic dystrophy type 1. - Lost Revenue: The pelacarsen miss eliminates anticipated royalty and milestone economics for Ionis. - Pipeline Scrutiny: The back-to-back failures deepen investor concerns regarding the broader RNA-targeted cardiovascular and neuromuscular pipeline. - Analyst Downgrades: Major Wall Street firms (including Goldman Sachs and Barclays) slashed their price targets following the trial misses. - Overshadowed Approval: Recent FDA approval and commercial pricing for Zanvastro (for Alexander disease) has failed to offset broader pipeline sentiment. Would you like me to review the upcoming catalysts and trial readouts left on Ionis' calendar, or analyze its current cash runway and balance sheet following these setbacks?
Ionis Pharmaceuticals shares fell 4.10% to $44.84, pressured by a confluence of sector headwinds and company-specific concerns. Broad healthcare weakness (XLV down over 1%) driven by rising Treasury yields, oil prices above $90/barrel, and U.S.-Iran geopolitical tensions weighed on the biotech sector. Overlaid on that backdrop, lingering investor caution about Ionis's July Phase 3 trial failure for eplontersen and scrutiny over a $546 million equity shelf offering tied to an ESOP further dampened sentiment ahead of the Zilganersen PDUFA decision.
Ionis Pharmaceuticals fell 2.04% to $46.28 following a Phase 3 clinical trial miss for pelacarsen (partnered with Novartis), which failed to meet its primary cardiovascular endpoint, according to reports cited by finance.yahoo.com and marketwatch.com. The decline extends a multi-day selloff triggered by this setback and compounded by July's earlier eplontersen trial failure; volume of 3.0M shares runs 1.55x normal for this point in the session.
In-depth IONS event analyses
Permanent, dated analyses of IONS's most significant sessions.
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS rose 1.6% to $39.42. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IONS stock rise?
IONS gained 1.60% ($0.62) versus the prior close of $38.80, last trading at $39.42 on 0.8× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-11-09 — about 2 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $84.92, about 115.4% above the current $39.42. Over the past 90 days, analysts recorded 2 upgrades, 13 maintains, and 1 downgrade.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IONS-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 7, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
